Companies looking to offer psychedelic drug therapy coverage for employees
New York Post, April 12, 2024
A growing number of companies are exploring the possibility of offering psychedelic therapy for their employees as a cost-saving and effective means of mental health treatment, according to a report.
Antidepressant prescriptions soar among UK children
UnHerd, April 2, 2024
New figures suggest nearly 500,000 antidepressant prescriptions are being given to children each year, with only one in four having visited a child psychiatrist before they were given the medicines.
Better sex beyond the trip: Enhanced sexual functioning months after a psychedelic experience
Open Foundation, March 24, 2024
“This study shines yet more light on the far-reaching effects of psychedelics on an array of psychological functioning.” Dr David Erritzoe, Clinical Director of the Centre for Psychedelic Research.
Denver Begins Psychedelic Training For First Responders
Dabbin-Dad, March 17, 2024
MAPS has partnered with the City and County of Denver to provide comprehensive training on psychedelic crisis assessment and intervention to the city’s first responders.
How Psychedelics Could Help Soldiers Overcome Trauma
Time, March 10, 2024
Amid this mental health catastrophe, authorities have begun turning to psychedelics for help—and for good reason.
Single dose of LSD provides immediate and lasting relief from anxiety, study says
CNN, March 7, 2024
A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder.
Thanks to this man, MDMA could soon be legal for therapy
The Guardian, March 1, 2024
Rick Doblin is a psychedelic pioneer – and he thinks it can help us save the world, one trauma-ending trip at a time.
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
Incannex Healthcare, February 28, 2024
Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalised anxiety disorder (GAD). The trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.
How Psychedelics Could Become The Medicine Of The Future
The Project, February 28, 2024
Australian researchers are revolutionising mental health treatment, with the country becoming the first to legalise the use of psychedelics as treatment.
Shannon is terminally ill. In a trailblazing trial, she took a white pill
The Sydney Morning Herald, February 24, 2024
In a groundbreaking Australian study, Shannon Turner and 34 other terminally ill patients used psychedelics for their end-of-life treatment. They lift the lid on what it was like.
Read the full PDF article here.
Mind Medicine Australia is proud to be a part funder of the St Vincent’s trial.
Exercise twice as effective as antidepressants
The Telegraph, February 15, 2024
Exercise is twice as effective at treating depression as antidepressants, a study has suggested.
ISRAELI GROUP TO STUDY MDMA THERAPY FOR OCTOBER 7 SURVIVORS WITH PTSD
The Intercept, February 14, 2024
The patients would undergo two sessions with the drug each in small groups, in what would be the largest MDMA-assisted therapy study anywhere to date — a milestone in the passage of psychedelic medicine into mainstream acceptance.
Psychedelics may help treat PTSD—and the VA is intrigued
National Geographic, February 13, 2024
Demand from veterans for psychedelic medicine is poised to explode as research suggests it might help with post-traumatic stress disorder and depression.
First patient to be dosed with psychedelic drugs hails the therapy
The Australian, February 12, 2024
Claire Danko never intended to make medical history. The 38-year-old Melbourne woman, who for years had suffered debilitating symptoms of post-traumatic stress disorder, just wanted mental relief.
New Study Links Psychedelic Experiences To Better Sex
Forbes, February 8, 2024
Psychedelics including psilocybin and LSD may improve sexual function for months after a psychedelic experience, according to a new study from researchers at Imperial College London.
Reckoning looms for depression drugs
The Australian, January 28, 2024
The world’s first psychiatry guidelines on de-prescribing antidepressants have sparked a fierce debate in medicine as the debunked ‘chemical imbalance’ theory comes under scrutiny.
EU to Fund Study of Psilocybin for Patients in Palliative Care
Filter Magazine, January 26, 2024
The European Union is putting money into a psychedelic study with patients who are receiving palliative care for incurable illnesses.
European Union Funds Groundbreaking Research Into Psychedelic Therapy
Open Foundation, January 24, 2024
A European consortium of 19 partners has been awarded over €6.5M by the European Union to study psilocybin to treat psychological distress in people with progressive incurable illnesses requiring palliative care.
Australian psychiatrist co-authors first antidepressant deprescribing guidelines
The Australian, January 22, 2024
Growing disquiet about the over prescription of antidepressants has been acknowledged in the first guidelines on deprescribing, with doctors being told the benefits of the drugs will be outweighed in some patients by adverse effects.
Field trip: inside America’s first magic mushroom school
The Guardian, January 14, 2024
At a forest facility in Oregon, the first US state to allow supervised use of the medicine, students work toward becoming licensed trip facilitators.